The authors of the study conclude that “KAT offers clinically meaningful improvements and demonstrated a desirable safety and risk mitigation profile”. Ongoing ketamine-based medication sessions enhance therapeutic benefits by preventing the 90% relapse rate that is often seen in single-infusion ketamine-based treatments (Kryst et al., 2020).
Hull et al. (2022) take this standpoint to reiterate the use of dissociative and psychedelic compounds for reducing important symptoms of common mental health disorders such as reducing suicidal ideation and behaviour. This could be viewed as an exaggeration, especially since the mechanism of dissociation is still relatively unknown in terms of how it reduces anxiety and depression symptoms (Liu et al., 2020).
This review concluded that people living with depression are at considerable risk of internalising negative stereotypes and discrimination associated with depression. Prominent risk factors were identified, including depression symptom severity and stigma-related factors; but protective factors were also identified, such as quality of life and self-esteem.
The study reinforces findings from the existing literature that, in the context of comorbid anxiety and depression, anxiety seems to have an earlier age of onset. Early identification and intervention for anxiety disorders may therefore help to prevent the developmental of other comorbid psychiatric disorders, such as depression or additional anxiety disorders.
Patients showed a stronger preference for CAT-GSH, compared to CBT-GSH, and CAT-GSH participants were found to be more likely to complete full treatment. However, findings seem to indicate that preference accommodation did not have an impact on clinical outcomes, and the two GSH versions evaluated were found to be equally effective treatment options for the treatment of anxiety. Hence, CAT-GSH may represent an effective and well-tolerated option that could be offered to anxious patients in primary care settings.
T. Itatsu, A. Nagahara, M. Hojo, A. Miyazaki, T. Murai, M. Nakajima, und S. Watanabe. Internal medicine (Tokyo, Japan), 50 (7):
713-7(Januar 2011)JID: 9204241; 0 (Serotonin Uptake Inhibitors); 2011/04/01 epublish; ppublish; Confusió absoluta entre cas-control i exposats-no exposats<br/><br/><br/>Tipus d'estudis.